A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-13

Study Completion Date

2023-08-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to explore the optimal dose and administration of the experimental drug, and to evaluate the safety and efficacy of the drug in patients with renal anemia. Patients with renal anemia on regular dialysis treatment are expected to be enrolled in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis

NCT02586402

Chronic Renal Failure Anemia Dialysis

UNKNOWN PHASE2

Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis

NCT03902691

Chronic Kidney Diseases

COMPLETED PHASE3

A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

NCT04231292

Patient of Anemia in Chronic Renal Failure With Hemodialysis

UNKNOWN PHASE2

Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis

NCT02403362

Chronic Renal Failure Chronic Kidney Disease Anemia

UNKNOWN PHASE2

Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

NCT00752609

Anemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multi-center, randomized, open-label, positive controlled phase II clinical study. A total of 125 to 150 patients with renal anemia receiving regular dialysis were enrolled in this study. Those patients were randomly allocated to 5 treatment groups in a ratio of 1:1:1:1:1, with 25 to 30 patients in each group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A1

Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)\* 0.004 (conversion coefficient), Q2W for administration.

Group Type EXPERIMENTAL

Recombinant human erythropoietin injection

Intervention Type BIOLOGICAL

The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).

B1

Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)\* 0.008 (conversion coefficient), Q2W for administration.

Group Type EXPERIMENTAL

Recombinant human erythropoietin injection

Intervention Type BIOLOGICAL

The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).

A2

Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)\* 0.004 (conversion coefficient), Q4W for administration.

Group Type EXPERIMENTAL

Recombinant human erythropoietin injection

Intervention Type BIOLOGICAL

The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).

B2

Recombinant human erythropoietin injection; Weekly dose of short-acting EPO (IU/kg)\* 0.008 (conversion coefficient), Q4W for administration.

Group Type EXPERIMENTAL

Recombinant human erythropoietin injection

Intervention Type BIOLOGICAL

The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).

C

Human erythropoietin injection；Refer to the product instructions.

Group Type ACTIVE_COMPARATOR

Human erythropoietin injection

Intervention Type BIOLOGICAL

Refer to the product instructions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recombinant human erythropoietin injection

The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).

Intervention Type BIOLOGICAL

Human erythropoietin injection

Refer to the product instructions

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female patients at the age of 18\~75 (including critical value).
2. Patients clinically diagnosed with renal anemia who have received dialysis for at least 12 weeks (hemodialysis≥3 times/week, total urea clearance index (Kt/V) ≥1.2 or urea reduction rate (URR) ≥65%; peritoneal dialysis≥4 times/day, weekly Kt/V≥1.7);
3. Hb in screening period should be within the range of 100\~130g/L (including both ends), and the deviation should not exceed 10g/L;
4. Iron status (TSAT ≥20% or SF ferritin ≥100μg/L) during screening.
5. Have been stably treated with short-acting EPO 1-3 times per week for at least 12 weeks before baseline;
6. Consent to use reliable contraceptive methods and no family planning from the screening period to 3 months after the last administration；
7. Voluntarily participate in the trial and sign the informed consent form.

Exclusion Criteria

1. Patients with a history of severe allergies (including drug allergies), especially allergic to erythropoietin, or to any component of the test drug (e.g. polyethylene glycol);
2. Have a history of kidney transplantation or plan to undergo kidney transplantation during the trial；
3. Have any other disease that causes chronic anemia (e.g., sickle cell anemia, myelodysplastic syndrome, hematologic malignancy, myeloma, hemolytic anemia, pure red cell aplastic anemia) or PRCA following therapy of erythropoietin protein;
4. Suffered from acute or chronic blood loss (such as gastrointestinal bleeding) or undergwent surgical procedures due to massive bleeding within 3 months before screening, or plan to have a surgery during the clinical trial (except for arteriovenous fistula or peritoneal dialysis tube adjustment);
5. Have a history of malignant tumors within the past 5 years (excluding non-melanoma skin cancer or excised carcinoma in situ);
6. Suffer from autoimmune diseases (such as rheumatoid arthritis or systemic lupus erythematosus) or diseases of endocrine system (such as poorly controlled diabetes mellitus complicated with peripheral vascular diseases, severe secondary hyperparathyroidism \[parathyroid hormone \> 800ng/L\]);
7. Received systemic antibiotic treatment or C-reactive protein ≥30mg/L within 4 weeks due to severe infection before screening;
8. The following conditions occur during screening period:

Hepatic dysfunction (AST or ALT\>3 times ULN); Coagulation dysfunction (activated partial thrombin time \> 1.5 times ULN); Folic acid or vitamin B12 deficiency (serum folic acid level \<LLN, vitamin B12 \<LLN); Positive for HBsAg, HBcAb, HIV-ABb, HCV-AbB or TP-Ab;
9. Suffer from severe thromboembolic disease, poorly controlled severe hypertension (SBP before dialysis \> 170mmHg or DBP ≥100mmHg) or hypotension (SBP before dialysis \<90mmHg);
10. Suffer from severe cardiovascular and cerebrovascular disease, severe or unstable coronary artery disease, heart failure (NYHA CLASS III or IV), or those who received coronary artery bypass grafting or percutaneous coronary intervention within 6 months, or those who had a history of myocardial infarction or stroke within 3 months;
11. Received androgen therapy or blood transfusion within 8 weeks before screening period;
12. Received long-acting ESAs within 3 months or HIF-PHI (e.g., rosalat) within 2 weeks before initial administration;
13. Participated in other clinical trials as a subject within 4 weeks before screening period or the duration from the last administration to enrollment was shorter than the 5 half-lives of the drug;
14. Have a history of epileptic seizures or mental illness;
15. Alcoholism, drug abuse or drug addiction
16. Pregnant or breastfeeding;
17. Investigator considers not suitable to enter this trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No